Clinical trial

Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001

NCT03574818

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2018-05-29

PhasePHASE2

Study timeline

Study start (actual)2018-05-29Date precision: day

Registry last updated2020-03-18

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Squamous Cell Lung Cancerunresolved

Interventions

Necitumumab-Gemcitabine-CisplatinDRUG

Evaluation to determine if patient is a candidate to proceeed with surgical resection or notDIAGNOSTIC_TEST

Sponsors & collaborators

Montefiore Medical Centerlead sponsor

Eli Lilly and Companycollaborator

Mapped research locations

The BronxNew York, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03574818 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.